GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forte Biosciences Inc (NAS:FBRX) » Definitions » EV-to-EBITDA

Forte Biosciences (Forte Biosciences) EV-to-EBITDA : 0.31 (As of May. 12, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Forte Biosciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Forte Biosciences's enterprise value is $-9.98 Mil. Forte Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-32.48 Mil. Therefore, Forte Biosciences's EV-to-EBITDA for today is 0.31.

The historical rank and industry rank for Forte Biosciences's EV-to-EBITDA or its related term are showing as below:

FBRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -5435826.88   Med: 0   Max: 544572.82
Current: 0.31

During the past 4 years, the highest EV-to-EBITDA of Forte Biosciences was 544572.82. The lowest was -5435826.88. And the median was 0.00.

FBRX's EV-to-EBITDA is ranked better than
84.42% of 462 companies
in the Biotechnology industry
Industry Median: 9.49 vs FBRX: 0.31

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Forte Biosciences's stock price is $0.745. Forte Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.040. Therefore, Forte Biosciences's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Forte Biosciences EV-to-EBITDA Historical Data

The historical data trend for Forte Biosciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forte Biosciences EV-to-EBITDA Chart

Forte Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
-28.82 0.49 1.45 0.22

Forte Biosciences Quarterly Data
Jun19 Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.45 0.81 0.35 0.71 0.22

Competitive Comparison of Forte Biosciences's EV-to-EBITDA

For the Biotechnology subindustry, Forte Biosciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forte Biosciences's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forte Biosciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Forte Biosciences's EV-to-EBITDA falls into.



Forte Biosciences EV-to-EBITDA Calculation

Forte Biosciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-9.975/-32.48
=0.31

Forte Biosciences's current Enterprise Value is $-9.98 Mil.
Forte Biosciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Forte Biosciences  (NAS:FBRX) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Forte Biosciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.745/-1.040
=At Loss

Forte Biosciences's share price for today is $0.745.
Forte Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.040.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Forte Biosciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Forte Biosciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Forte Biosciences (Forte Biosciences) Business Description

Traded in Other Exchanges
Address
3060 Pegasus Park Drive, Building 6, Dallas, TX, USA, 75247
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease ("GvHD"), vitiligo and alopecia areata ("AA"). The company is developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and pediatric patients with atopic dermatitis. It plans to advance FB-401 into a randomized Phase 2 clinical trial.
Executives
Paul A. Wagner director, officer: See Remarks C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
Scott C. Brun director C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Hubert C Chen officer: See remarks C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Stephen K Doberstein director 129 ELSIE STREET, SAN FRANCISCO CA 94110
Barbara K Finck director C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Antony A Riley officer: Chief Financial Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
Thomas E Darcy director C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121
Donald Allen Williams director C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
Patricia S Walker director 5540 EKWILL ST STE D, SANTA BARBARA CA 93111
Lawrence Eichenfield director C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Steven Kornfeld director C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Steven Michael Oliveira 10 percent owner 18 FIELDSTONE COURT, NEW CITY NY 10956
Fairooz Kabbinavar officer: SVP Clinical Development C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark G Foletta officer: EVP & Chief Financial Officer AMYLIN PHARMACEUTICALS INC, 9360 TOWNE CENTRE DR, SAN DIEGO CA 92121